Enhancing Rehabilitation in Aging Study (ERAS)
ConditionAdults
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age40-79
SponsorUniversity of Florida
About this trial
Acute Intermittent Hypoxia (AIH) is a rehab approach attributed to serotonin. AIH signaling also occurs via adenosine, and the pathways inhibit each other. Increased neural adenosine in aging may stymie AIH plasticity. The hypothesis is pre-treatment with adenosine 2A receptor inhibition (A2AI) enhances AIH effects on motor plasticity in unaffected adults. AIH exposures will be paired with A2AI or placebo, with a 4-week washout. Primary outcome measures include inspiratory and grip strength.
Eligibility criteria
Qualifiers
Aged 40-79 years Non-smokers Ambulatory in the community Do not require assistance to complete activities of daily living
Disqualifiers
Restrictive or obstructive lung conditions Pregnancy Active respiratory infections Use of antibiotics in the last 4 weeks Symptomatic cardiac disease BMI >35 kg/m2 Seizure disorder or progressive neurological condition Uses positive pressure mechanical ventilation when awake and upright, or oxygen assistance at any time
Trial design
Treatments tested in this trial
- Istradefylline 20 mg
- Placebo
- Acute Intermittent Hypoxia (AIH)
Treatment groups
38 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov